Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
William Greenhalf(University of Liverpool), Markus W. Büchler(Heidelberg University), Eithne Costello(University of Liverpool), Julia Mayerle(Ludwig-Maximilians-Universität München), Richard Jackson(University of Liverpool), Charlotte Rawcliffe(University of Liverpool), Elizabeth O. Garner(University of Liverpool), Paula Ghaneh(University of Liverpool), F Lacaine(Sorbonne Université), Daniel H. Palmer(Cancer Research UK Clinical Trials Unit), Andrew Scarfe(Cancer Institute (WIA)), John R. Mackey(University of Alberta), Attila Oláh(Semmelweis University), Ross Carter(Glasgow Royal Infirmary), John P. Neoptolemos(University of Liverpool), Bengt Glimelius(Uppsala University), Richard Charnley(Freeman Hospital), Juan W. Valle(The Christie NHS Foundation Trust), Niall C. Tebbutt(Peter MacCallum Cancer Centre), Alan Anthoney(St James's University Hospital), Christopher Halloran(University of Liverpool), Trevor F. Cox(University of Liverpool), Fiona Campbell(University of Liverpool), Mark R. Middleton(University of Oxford), Claudio Bassi(University of Verona), Christos Dervenis(Agia Olga Hospital), Richard F. Lamb(Cancer Research UK), Jennifer Shannon(The University of Sydney), Alexander McDonald(Beatson West of Scotland Cancer Centre), David Goldstein(Prince of Wales Hospital), Aldo Scarpa(University of Verona), Mark Deakin, Malcolm J. Moore(University Health Network)
Cited by 333
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k